Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
"Prostate cancer resistant to conventional treatment could be all but wiped out by a therapy that boosts the immune system," the Daily Mail reports.
Immunotherapy is a type of therapy that uses the body's own immune system to help fight cancer. Immunotherapy may help the body's immune system ...
... they've also come to realize that yearly screenings for women who don't have a history of cervical cancer or a weakened immune system doesn't ...
These immune system-derived killers are cells that have been genetically reengineered to express receptors that allow them to recognize and ...
Dr Nizar Tannir discussed the development of new the immunotherapies – cancer vaccines that aim to stimulate the innate cancer immune response, ...
Melanoma is the deadliest form of skin cancer. According to ... Dr. Agarwala has special interest and expertise in immunotherapy for cancer. He has ...
These vaccinations are intended to treat cancer by stimulating the immune system so it can recognise and attack cancer cells, without harming normal ...
Researchers at Moffitt Cancer Center hope to improve NSCLC patient ... in the activation of the immune system,” explained Matthew Schabath, Ph.D., ...
Also, breast milk has antibodies, which are helpful for a baby's immune system to ward off viruses and bacteria. Surprisingly, breastfeeding may have ...
Top Highlights From the 2015 AACR Annual Meeting
This slide show features some of the top highlights from the 2015 American Association for Cancer Research (AACR) Annual Meeting.
This slide show features some of the top highlights from the 2015 American Association for Cancer Research (AACR) Annual Meeting.
While it's clear that too much sun can increase the risk for skin cancer, a new study has found that too little vitamin D can increase the risk of pancreatic ...
... the antibodies, the researchers were able to eliminate six different types of cancer - two melanomas, lymphoma, breast, lung and pancreatic cancer.
“It's like I never had [cancer], and I was ready to die.” ... It's also testing T-VEC in patients with solid tumors, pancreatic cancer, and squamous cell ...
Take for example pancreatic cancer; just 4 percent of pancreatic cancer sufferers in Britain are still alive five years after diagnosis. This survival rate ...
Triple Combination Elicits Responses in Pancreatic Cancer: Adding the drug cisplatin to the standard-of-care combination of albumin-bound paclitaxel ...
For instance, the Phase 1b biomarker-delineated response rates and survival data for tarextumab in pancreatic cancer is similar to the preclinical ...
According to the company, pancreatic cancer affects approximately 45,300 people in the EU at any given time, occurring at a frequency of about 0.88 ...
Science Daily Cancer News
A comprehensive genetic review of treatment strategies for glioblastoma brain tumors covers how these highly invasive and almost-always-deadly brain cancers may be treated, reviews the continuing challenges faced by researchers and clinicians, and presents the hope for better treatments by harnessing the power of the human genome.
The first population-based study that characterizes the association and temporal relationship between gastrointestinal stromal tumors (GIST) and other cancers has been conducted by researchers. The results indicate that one in 5.8 patients with GIST will develop additional malignancies before and after their diagnosis.
A new treatment for melanoma could be on the horizon, thanks to a recent finding. In the study, authors report that they found high levels of an enzyme in melanoma samples that they believe is a potential drug target.
When common chemotherapy drugs damage DNA in cancer cells, the cells can’t replicate. But the cells do have ways to repair the DNA and the cancer drugs aren’t effective to do so. Researchers have developed a way to find where this DNA repair happens. Their goal is to increase the potency of cancer drugs.
Link between inherited genetic variations, outcomes of non-small cell lung cancer patients discovered
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Patients diagnosed with NSCLC have a poor prognosis, with a 5-year survival rate of only 16 percent. Researchers hope to improve NSCLC patient survival with the results of a study that found that inherited genetic variations in interleukin genes are associated with improved patient survival and response to therapy.
Performing vigorous physical activity over one's lifetime may lower risk for non-Hodgkin lymphoma. Because not much is known about what causes non-Hodgkin lymphoma, identifying risk factors is particularly important for the prevention and control of this cancer, the main researcher noted.
The number of surgeries performed on terminally ill cancer patients has not dropped in recent years, despite more attention to the importance of less invasive care for these patients to relieve symptoms and improve quality of life.
A distinct pattern in the changing length of blood telomeres, the protective end caps on our DNA strands, can predict cancer many years before actual diagnosis, a new study shows. The pattern, which spanned 13 years before cancer diagnosis, could yield a new biomarker to predict cancer development with a blood test. This is the first reported trajectory of telomere changes over the years in people developing cancer.
Tambahkan Komentar